Abstract: Provided is use of an antibody-drug conjugate targeting Her2 in the preparation of a medicine for treating breast cancer patients with liver metastasis or breast cancer patients without lung metastasis. Compared with a control drug group (lapatinib+capecitabine), the application of the antibody-drug conjugate provided in the treatment of breast cancer patients with liver metastasis and in the treatment of breast cancer patients without lung metastasis can significantly improve the survival time of the patients.

Abstract: Implementations of the present disclosure relate to link failure detection. In the implementations, an access point (AP) determines a power save mode of each of a plurality of links established between the AP and a station. If at least two links of the plurality of links are in a power save mode, the AP determines a detection time period for detecting signals based on beacon intervals of the at least two links. The AP then transmits detection signals to the station in the at least two links during the detection time period. The AP determines connectivity of the at least two links based on responses to the detection signals received from the station. In this way, all the failed links in power save mode can be efficiently detected, thereby facilitating transmission scheduling between the AP and station.